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Abstract 
IL-12 is known to be an essential cytokine which appears to provide protective 
immunity against intracellular bacteria, such as Salmonella. In this study, we 
investigated the possibility of developing a vaccine using IL-12 against virulent 
Salmonella. We used the host defense system activated by cytokine IL-12. The highly 
virulent Salmonella strain (Salmonella typhimurium UK-1) was transformed with 
cytokine-expressing plasmids. These live, wild-type pathogens were used as vaccine 
strains without undergoing any other biological or genetic attenuating processes. The 
newly developed strains induced partial protection from infections (30-40%). Of note, 
the interleukin-12 transformed pathogen was safe upon immunization with low doses 
(103 CFU), induced IgG responses, and stimulated protective immune responses against 
Salmonella Typhimurium in mice (80-100%). These results suggest that IL-12 induced 
attenuation of wild-type Salmonella in the host infection stage and vaccine development 
using the wild-type strain harboring IL-12 secreting plasmids may be considered as an 
alternative process for intracellular bacterial vaccine development without the 
inconvenience of time-consuming attenuation processes. 
Keyword : salmonella typhimurium; vaccine; interleukin-12; attenuation 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
09
.3
41
3.
1 
: P
os
te
d 
9 
Ju
l 2
00
9
Introduction 
IL-12, a heterodimeric cytokine, is composed of two subunits, p40 and p35. This 
cytokine is produced mainly by monocytes/macrophages and promotes the development 
and activity of cytotoxic T-lymphocytes, including natural killer cells, lymphokine-
activated killer cells, and macrophages. Consequently, IL-12 is now recognized as a 
critical cytokine for intracellular pathogens in immune responses 1. IL-12 has also been 
shown to have an adjuvant activity 2. Salmonella strains are intracellular pathogens 
inducing Th1 and Th2 immune responses 3, 4. The immune response to Salmonella 
infection has been studied extensively in mice. A child with Il-12 deficiency may be 
predisposed to severe infections due to poorly virulent Salmonella. It is suggested that 
IL-12 is essential to and appears specific for protective immunity to intracellular 
bacteria, such as Salmonella.  
Salmonella species are a common cause of enteric infection in humans and are 
associated with significant mortality all over the world. Salmonella strains were first 
used as a bioterror agent in 1984 5. This agent was a new, modified strain of existing 
bacteria. Similarly to these Salmonella strains, bioterror agents are modified to evade 
detection by existing diagnostic, as well as treatment measures 6. In the age of the 
bioterror menace, bioterror agents could be modified to cause outbreaks of infectious 
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diseases which cannot be cured with existing treatments. The development of rapid and 
new treatment measures against unknown and modified bioterror agents is necessary to 
cope with this bioterror situation 1, 2, 3. Existing vaccines, however, are developed by the 
attenuation of pathogens through the genetic modification process. In addition, vaccines 
were prepared from the DNA of pathogens or from killed pathogens 4, 5, 6. These vaccine 
development processes were extremely time-consuming. Furthermore, existing vaccines 
are useless for protecting the public and the military health systems against bioterror 
that requires rapid, new vaccine development against pathogens used as bioweapons 
during wartime 7, 8. We used a wild-type organism without the chemical and biological 
attenuation process. The use of the wild-type strain can shorten the vaccine 
development process. Instead of the attenuation of pathogens or other processes 
required for the preparation of vaccine, we used a means of stimulating the host defense 
system at infected sites to prepare the vaccine. We speculated that the host defense 
system could play a more crucial role in the prevention of infectious agents than the 
virulence of unknown infectious agents. Thus, we postulated that the infection of this 
lethal strain with host-stimulating cytokine might induce protective immunity.  
In this study, we investigated the possibility of vaccine development using IL-12 against 
virulent Salmonella. We used the host defense system activated by cytokine IL-12. The 
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highly virulent Salmonella strain (Salmonella typhimurium UK-1) was transformed with 
cytokine-expressing plasmids. These live wild-type pathogens were used as vaccine 
strains without other biological and genetic attenuating processes. 
To test this hypothesis, we applied this concept to the preparation of Salmonella 
typhimurium vaccine in mice. S. typhimurium UK-1 is highly virulent for chickens and 
mice.  
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Material and Methods 
 
Bacterial strains and transformation of S. typhimurium. Salmonella typhimurium wild-
type strain UK-1 was grown in Luria-Bertani (LB) medium. Cytokine-expressing 
plasmids (Bank for Cytokine Research, Korea) were transformed into E.coli DH5a. To 
form the transformed DH5a, plasmids were extracted and again transformed into S. 
typhimurium SF586. The plasmids which had formed the transformed SF586 were again 
transformed to S. typhimurium UK-1. 
 
Bacterial challenges. Bacterial inocula of S. typhimurium were grown in Luria-Bertani 
(LB) medium to mid-log phase from single colonies. Bacteria were pelleted, re-
suspended in PBS, and quantified. Oral inoculation from a disposable syringe was used 
for oral challenges (103-108 c.f.u. of bacteria in 100µl PBS). The mice were returned to 
cages with food and bedding and carefully monitored. They were killed if they became 
moribund. For bacterial translocation studies, the mice were treated as above, and 7 
days after a single inoculation of 103 c.f.u, they were killed, their spleens were isolated 
and homogenized, and bacteria were plated in dilution on LB agar. 
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T cell proliferation assay. For salmonella antigen presentation in mice inoculated with 
salmonella harboring IL-12 secreting plasmid, CD4 T cells were obtained from spleens 
from salmonella inoculated mice by MACS systems(Miltenyi Biotec, Germany). 
Syngeneic unprimed T cells as APC treated with mitomycin C(0.5mg/ml) at 1×106 
cells/ml, pulsed with salmonella whole cell antigens (2ug/ml). Isolated CD4 T cells 
APCs were mixed 1:1 and incubated for 4days. Cell proliferation data obtained with 
Cell titer 96 AQuous One Solution Cell Proliferation assay(Promega, Co. USA). 
 
Cytokine and antibody ELISA. Sera were collected by eye-bleeding 2 weeks after the 
last inoculation. Sera were assayed for detection of IL-12 with a commercially available 
kit (Endogen, Boston, MA), according to the manufacturer's directions. HRP-conjugated 
streptoavidin and tetramethylbenzydime were used in the cytokine ELISA. The 
absorbance was read on a Universal Microplate reader (EL800) at 630nm. Elisa was 
also used to assay antibody responses to S. typhimurium. Polystyrene 96-well flat-
bottom microtiter plates were coated with lysates of S. typhimurium (2g per well). 
Sera obtained from the same experimental group were pooled. A 100ul volume of 
diluted samples was added to individual wells in duplicate and incubated for 2h at 37. 
Plates were then washed and HRP-conjugated goat anti-mouse IgG and IgA which had 
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been diluted 1:500 in blocking buffer were used as secondary antibodies. 
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Results  
Efficient induction of immune response with DNA plasmids orally delivered by 
Salmonella. 
When eukaryotic expression plasmid-bearing S. typhimurium were fed to BALB/c mice, 
the transformants would cross the intestinal epithelium via M cells. In the Peyer's 
Patches, they would then be phagocytosed by macrophages and dendritic cells, where 
the bacteria would die and release their plasmids. This acted to transfect the host cells 
and ultimately led to antigen expression. At the same time, the phagocytic cells would 
be activated due to the endotoxins of the bacterial carrier and, therefore, efficiently 
induce cytotoxic T-cells. The cytotoxic T-cells would, in turn, lyse the phagocytes. The 
release of antigen would subsequently induce helper T-cells and antibody 
production[REF+]. Thus, all of the specific arms of the immune system should be 
induced. Fig. 1 shows that this was, indeed, the case. In mice that had been immunized 
with Salmonella transformants that carried expression plasmids encoding IL-12, More 
IL-12 induction in blood production than with wild-type salmonella control strain was 
detected.  
 
Survival of wild-type S. typhimurium with cytokine-secreting plasmids. 
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To test whether such a strain would result in an immune response that would confer 
safety against a lethal infection with a pathogenic microorganism, we immunized mice 
with the recombinant Salmonella, as described above, and challenged them with various 
doses(103 - 108) 
Mice infected with S. typhimurium containing the interleukin-12 (IL-12) gene survived 
longer than mice infected with S. typhimurium containing other cytokine genes (data not 
shown). It is well known that IL-12 induces IFN-g production, which is thought to be 
crucial for protective immunity against intracellular microorganisms. This is supported 
by studies which used mice absent IL-12 or absent the IL-12 receptor16. These reports 
are in agreement with our results of the experimental infection of mice with Salmonella 
harboring IL-12 plasmids. However, the limited survival of mice infected with 108 CFU 
S. typhimurium harboring IL-12 plasmids had limited its therapeutic effectiveness. To 
determine the safe dose of our Salmonella strains in mice, we administered Salmonella 
orally at doses equivalent to 103, 104, 105, 106, 107, and 108 colony-forming units. All of 
the mice that received Salmonella survived longer than untreated control mice upon 
subsequent Salmonella infection. A single oral administration of a higher dose of 
Salmonella could not protect mice against the virulence of the Salmonella. Thus, we 
determined 103 CFU per mice to be the safety dose. Treated with this dose, nearly 100% 
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survival rate was obtained in mice infected orally with S. typhimurium strains (Fig. 2).  
 
Analysis of antibody responses to Salmonella following immunization with S. 
typhimurium UK-1 with IL-12 plasmids. 
To see whether bacteria containing cytokine genes could be used as vaccines, we orally 
immunized mice with the 103 CFU of S. typhimurium UK-1 harboring cytokine 
plasmids. The serum sample was collected at 2, 4 weeks after immunization and tested 
for antibodies to S. typhimurium in the ELISA. Increased levels of serum IgG were 
detected in mice infected with S. typhimurium UK-1 harboring cytokine plasmids (Fig. 
3A). The specific response to the Salmonella antigen was also evaluated by measuring 
the specific antibody in the serum. The level of IgG in the serum was significantly 
higher in mice treated with Salmonella than in control mice. Additionally, an elevation 
of IgA anti-Salmonella levels was observed after the immunization in all experimental 
groups (Fig 3B.) 
 
Proliferative responses to Salmonella antigen for Salmonella with IL-12 plasmids 
induced protection. 
To evaluate the ability of S. typhimurium UK-1 with IL-12 plasmids to activate T 
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lymphocytes, we cultured spleen cells of immunized animals and measured the 
proliferative response based on MTT-based assay. Salmonella with IL-12 plasmid-
primed splenocytes proliferated in response to Salmonella lysate antigen or ConA 
stimulation (Fig. 4). This finding demonstrates that Salmonella with IL-12 plasmids is 
able to activate primed murine T-cells more than non-transforming Salmonella that is a 
critical arm of the immune system involved in host protection against this parasitic 
infection.  
 
Adjuvant effect of IL-12 on Salmonella with IL-12 plasmid-induced protection. 
To measure the protection level induced by S. typhimurium UK-1 with IL-12 plasmid 
immunization associated to different adjuvant formulations, BALB/c mice were infected 
with a dose of 103 S. typhimurium UK-1. The protective effect was observed during the 
30-day post-challenge observation period. 80-100% of mice immunized with a single 
dose of S. typhimurium UK-1 harboring IL-12 plasmids were protected against the oral 
challenge of wild-type S. typhimurium UK-1 (Fig. 5). Vaccination with the attenuated 
strain (BRD509) alone at the same low dose induced 25% protection compared to their 
respective controls. These results indicate that immunization with IL-12 plasmid-
transforming S. typhimurium could be used as an effective vaccination. 
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Discussion 
Cytokines are the key communication molecules in host cells to defend against the 
enteric Salmonella pathogen. Infected with Salmonella, intestinal epithelial cells and 
macrophages produce multiple chemokines and proinflammatory cytokines in culture9. 
Among these, IL-12 is involved in differentiation of naïve CD4+ lymphocyte to the Th1 
subset, which produces, IFN-gamma, as well as  other cytokines. Many previous 
studies had tested this cytokine as an adjuvant in experimental infection models in 
which induction of Th1 responses is known to be critical for protective immunity. In 
particular, IL-12 is essential for the induction of protective immunity against 
intracellular bacteria, such as mycobacteria and Salmonella10, 11. More recently, the 
clinical observation that severe Salmonella disease is more likely in patients with IL-
12/IL-23 component deficiency than in patients with IFN-gamma component deficiency 
suggests that IL-12/IL-23 is a key cytokine  for immunity against Salmonella in 
humans and merits both further investigation into possible IFN-gamma  independent 
IL-12/IL-23 driven mechanisms of immunity, and dissection of the contributory role of 
IL-12 and IL-23. It also suggests a possible role for recombinant IL-12/IL-23 as 
immunotherapy for severe Salmonella disease.  
In the present study, we transformed plasmids with the cytokine gene, but did not use 
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general attenuation or modification processes. The process could be applied to develop 
vaccines against unknown pathogens, as it requi res neither characterization, nor 
genomic analysis. We used many cytokine genes for this Salmonella construction, 
selecting efficient strains harboring cytokine gene plasmids that induced protection in 
mice (data not shown). This wild-type pathogenic S. typhimurium UK1 harboring Il-12 
expressing plasmids induced protection upon administration with a lethal dose (Fig. 5). 
In the Salmonella harboring IL-12 plasmid vaccine model, IL-12 is involved in the 
protective response induced by administration and the level of protection is increased 
with co-administration of rIL-12. 
In the present study, we showed the ability of wild-type S. typhimurium UK1 (20-100%) 
in presence of IL-12 to induce partial protection against challenge in mice. 
The level of IL-12 which had increased more in blood following IL-12 administration is 
not the only mechanism involved in the enhanced protection observed in the S. 
typhimurium with IL-12 immunized group. T-cell proliferative responses from these 
individuals to Salmonella with plasmids totally enhanced the responses and are 
dependent on IFN-gamma, which suggests a Th1 pattern of immune response in the 
control of this parasitic disease.  
Although the vaccine presented here was not protective against challenge with high 
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doses of pathogens, the safety problem and the effectiveness with higher doses could be 
overcome by lowering the dose of wild bacteria for immunization or by using plasmids 
expressing high concentrations of protein. 
This investigation established that co-administration of IL-12expressing plasmids in the 
highly susceptible BALB/c mouse strain enhances survival against challenge with S. 
typhimurium. The enhanced protective effect was accompanied by an increased 
production of IL-12 in blood-associated susceptibility and immunity against 
salmonellosis.   
We also observed that the Salmonella harboring IL-12 plasmids induced antibody 
responses at low dose immunization, induced mucosal and humoral immunity, and 
showed protection (80-100%) against salmonellosis in mice, like other live attenuated 
vaccines. 
In conclusion, we have shown in this study that IL-12 is an important cytokine for 
increasing protection induced by a Salmonella harboring IL-12 expressing plasmid 
administration strategy in mice. These features would indicate that Salmonella 
harboring IL-12 plasmids are good candidates for the construction of live wild-type 
vaccine for Salmonella. 
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Fig 1. IL-12 expression in blood of mice inoculated with S. typhimurium harboring 
plasmid expressing interleukin-12. Mouse inoculate with a single dose of 103 c.f.u. S. 
typhimurium UK-1 harboring IL-12 plasmid (striped bars), non-treatment(white bars) or 
attenuated S. typhimurium UK-1 (black bars) 
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Fig 2. Challenge of mice with virulent S. typhimurium UK-1 with or without plasmid 
expressing interleukin-12. Survival curve comparing BALB/c mice after orally 
inoculation with A. 107 B. 106 C. 105 D. 104 E. 103 c.f.u. S. typhimurium 
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Fig. 3. antibody production in mice inoculated with S. typhimurium UK-1 harboring 
plasmid expressing interleukin-12. A, serum anti-salmonella IgG antibody responses in 
mice orally immunized with a single dose of 103 c.f.u. S. typhimurium UK-1 harboring 
IL-12 plasmid (striped bars), non-treatment(white bars) or attenuated S. typhimurium 
UK-1 (black bars) B, serum anti-salmonella IgA antibody responses in mice  
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Fig 4 T cell proliferation in mouse spleen cells after immunized with S. typhimurium 
UK-1 harboring plasmid expressing interleukin-12. CD4 T cells from mouse after orally 
inoculation with 103 c.f.u. S. typhimurium UK-1 harboring IL-12 plasmid (striped bars), 
non-treatment(white bars) or attenuated S. typhimurium UK-1(black bars) B, serum 
anti-salmonella IgA antibody responses in mice  
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 Fig 5. Protection of mice against lethal S. typhimurium UK-1 challenge by immunized 
with lethal S. typhimurium UK-1 harboring plasmid expressing interleukin-12. A. 
recovery of c.f.u of S. typhimurium from spleens B, survival curve after oral challenge 
with 103 c.f.u. lethal S. typhimurium 
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